Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Net Income: 2019-2025

Historic Net Income for Avidity Biosciences (RNA) over the last 7 years, with Sep 2025 value amounting to -$174.1 million.

  • Avidity Biosciences' Net Income fell 117.13% to -$174.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$548.5 million, marking a year-over-year decrease of 95.95%. This contributed to the annual value of -$322.1 million for FY2024, which is 52.18% down from last year.
  • According to the latest figures from Q3 2025, Avidity Biosciences' Net Income is -$174.1 million, which was down 11.11% from -$156.7 million recorded in Q2 2025.
  • In the past 5 years, Avidity Biosciences' Net Income ranged from a high of -$23.8 million in Q1 2021 and a low of -$174.1 million during Q3 2025.
  • For the 3-year period, Avidity Biosciences' Net Income averaged around -$89.1 million, with its median value being -$70.7 million (2024).
  • Data for Avidity Biosciences' Net Income shows a maximum YoY plummeted of 291.80% (in 2021) over the last 5 years.
  • Avidity Biosciences' Net Income (Quarterly) stood at -$38.5 million in 2021, then tumbled by 31.07% to -$50.5 million in 2022, then fell by 19.59% to -$60.3 million in 2023, then slumped by 69.81% to -$102.5 million in 2024, then crashed by 117.13% to -$174.1 million in 2025.
  • Its last three reported values are -$174.1 million in Q3 2025, -$156.7 million for Q2 2025, and -$115.3 million during Q1 2025.